Skip to main content

Frequency of TERT promoter mutations in primary tumors of the liver

Virchows Archiv volume 465, pages 673–677 (2014)Cite this article

Abstract

Transcriptional regulation of the TERT gene is a major cause of the cancer-specific increase in telomerase activity. Recently, frequent somatic mutations in the TERT promoter have been described in several tumor entities such as melanoma, glioblastoma, bladder cancer, and hepatocellular carcinoma. By generating a putative consensus binding site for ETS transcription factors within the TERT promoter, these mutations are predicted to increase promoter activity and TERT transcription. In order to improve the understanding of the role of TERT promoter mutation in liver tumorigenesis, the mutational status of the TERT promoter was analyzed in 78 hepatocellular carcinomas, 15 hepatocellular adenomas, and 52 intrahepatic cholangiocarciomas. The promoter region of TERT was screened for the two hotspot mutations using PCR and restriction fragment length analysis, utilizing the introduction of novel restriction sites by the somatic mutations. TERT promoter mutation was found in 37 of 78 hepatocellular carcinomas (47 %) and was restricted to the -124C>T mutation. Frequency of mutations was associated with grade of differentiation ranging from 39 % in well-differentiated tumors to 73 % in high-grade hepatocellular carcinomas. TERT promoter mutations were not found in 15 hepatocellular adenomas and 52 intrahepatic cholangiocarcinomas. These data show that TERT promoter mutation is the most frequent genetic alteration in hepatocellular carcinoma known at this time. The striking predominance of the -124C>T mutation compared with other tumor entities suggest a biological difference of the two hotspot mutations. Analysis of TERT promoter mutation might become a diagnostic tool distinguishing hepatocellular adenoma from well-differentiated hepatocellular carcinoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Mocellin S, Pooley KA, Nitti D (2013) Telomerase and the search for the end of cancer. Trends Mol Med 19(2):125–133. doi:10.1016/j.molmed.2012.11.006

    CAS  PubMed  Article  Google Scholar 

  2. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961. doi:10.1126/science.1230062

    CAS  PubMed  Article  Google Scholar 

  3. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959. doi:10.1126/science.1229259

    CAS  PubMed  Article  Google Scholar 

  4. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110(15):6021–6026. doi:10.1073/pnas.1303607110

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  5. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218. doi:10.1038/ncomms3218

    PubMed Central  PubMed  Article  Google Scholar 

  6. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R (2013) TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 110(43):17426–17431. doi:10.1073/pnas.1310522110

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  7. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185. doi:10.1038/ncomms3185

    PubMed  Article  Google Scholar 

  8. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0

    PubMed  Article  Google Scholar 

  9. Liu S, Chan KW, Wang B, Qiao L (2009) Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 104(10):2617–2624. doi:10.1038/ajg.2009.440, quiz 2625

    PubMed  Article  Google Scholar 

  10. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M (2008) Malignant transformation of hepatic adenomas. Mod Pathol 21(4):491–497. doi:10.1038/modpathol.2008.8

    CAS  PubMed  Article  Google Scholar 

  11. Nault JC, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144(5):888–902. doi:10.1053/j.gastro.2013.02.032

    CAS  PubMed  Article  Google Scholar 

  12. Patel T (2006) Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3(1):33–42. doi:10.1038/ncpgasthep0389

    PubMed  Article  Google Scholar 

  13. Nzeako UC, Goodman ZD, Ishak KG (1995) Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 76(4):579–588

    CAS  PubMed  Article  Google Scholar 

  14. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. World Health Organizatin Classification of Tumours, 4 edn.,

  15. Chan SH, Opitz L, Higgins L, O’Loane D, Xu SY (2010) Cofactor requirement of HpyAV restriction endonuclease. PLoS ONE 5(2):e9071. doi:10.1371/journal.pone.0009071

    PubMed Central  PubMed  Article  Google Scholar 

  16. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65(2):360–366. doi:10.1016/j.eururo.2013.08.052

    CAS  PubMed  Article  Google Scholar 

  17. Hurst CD, Platt FM, Knowles MA (2014) Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 65(2):367–369. doi:10.1016/j.eururo.2013.08.057

    CAS  PubMed  Article  Google Scholar 

  18. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73(24):7162–7167. doi:10.1158/0008-5472.CAN-13-2498

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  19. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, Chen C, Lv Z, Tang A, Sun X, Lu J, Li W, Zhou J, Gui Y, Zhou F, Wang D, Cai Z (2014) Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol 65(2):274–277. doi:10.1016/j.eururo.2013.10.038

    CAS  PubMed  Article  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Affiliations

  1. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany

    Alexander Quaas, Theresa Oldopp, Lars Tharun, Catina Klingenfeld, Till Krech, Guido Sauter & Tobias J. Grob

Authors
  1. Alexander Quaas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theresa Oldopp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars Tharun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catina Klingenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Till Krech
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guido Sauter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tobias J. Grob
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias J. Grob.

Additional information

Alexander Quaas and Theresa Oldopp contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Quaas, A., Oldopp, T., Tharun, L. et al. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch 465, 673–677 (2014). https://doi.org/10.1007/s00428-014-1658-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-014-1658-7

Keywords

  • TERT promoter mutation
  • Hepatocellular carcinoma
  • Hepatocellular adenoma
  • Intrahepatic cholangiocarcinoma